Bioequivalence of a FDC Tablet of Linagliptin/Metformin (2.5mg/750mg) Extended Release in Healthy Subjects

NCT02121509 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

74

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy

Interventions

DRUG: Linagliptin
DRUG: Linagliptin/Metformin ER FDC
DRUG: Metformin ER

Sponsor

Boehringer Ingelheim

Collaborators

[object Object]